334 related articles for article (PubMed ID: 17047042)
1. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.
Goldstein AM; Chan M; Harland M; Gillanders EM; Hayward NK; Avril MF; Azizi E; Bianchi-Scarra G; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cannon Albright LA; Demenais F; Elder DE; Ghiorzo P; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; Mackie RM; Magnusson V; Mann GJ; Niendorf K; Newton Bishop J; Palmer JM; Puig S; Puig-Butille JA; de Snoo FA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E;
Cancer Res; 2006 Oct; 66(20):9818-28. PubMed ID: 17047042
[TBL] [Abstract][Full Text] [Related]
2. Familial melanoma, pancreatic cancer and germline CDKN2A mutations.
Goldstein AM
Hum Mutat; 2004 Jun; 23(6):630. PubMed ID: 15146471
[TBL] [Abstract][Full Text] [Related]
3. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
5. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
6. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
[TBL] [Abstract][Full Text] [Related]
8. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LA; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; ;
J Med Genet; 2007 Feb; 44(2):99-106. PubMed ID: 16905682
[TBL] [Abstract][Full Text] [Related]
9. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
[TBL] [Abstract][Full Text] [Related]
10. Novel and recurrent p14 mutations in Italian familial melanoma.
Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P
Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
12. Novel CDKN2A mutations in Austrian melanoma patients.
Burgstaller-Muehlbacher S; Marko M; Müller C; Wendt J; Pehamberger H; Okamoto I
Melanoma Res; 2015 Oct; 25(5):412-20. PubMed ID: 26225579
[TBL] [Abstract][Full Text] [Related]
13. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia.
Ghiorzo P; Ciotti P; Mantelli M; Heouaine A; Queirolo P; Rainero ML; Ferrari C; Santi PL; De Marchi R; Farris A; Ajmar F; Bruzzi P; Bianchi-Scarrà G
Int J Cancer; 1999 Nov; 83(4):441-8. PubMed ID: 10508477
[TBL] [Abstract][Full Text] [Related]
14. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
Auroy S; Avril MF; Chompret A; Pham D; Goldstein AM; Bianchi-Scarrà G; Frebourg T; Joly P; Spatz A; Rubino C; Demenais F; Bressac-de Paillerets B;
Genes Chromosomes Cancer; 2001 Nov; 32(3):195-202. PubMed ID: 11579459
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
16. FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma.
Holland EA; Lo S; Kelly B; Schmid H; Cust AE; Palmer JM; Drummond M; Hayward NK; Pritchard AL; Mann GJ
Fam Cancer; 2021 Jul; 20(3):231-239. PubMed ID: 32989607
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A mutations in melanoma families from Uruguay.
Larre Borges A; Cuéllar F; Puig-Butillé JA; Scarone M; Delgado L; Badenas C; Milà M; Malvehy J; Barquet V; Núñez J; Laporte M; Fernández G; Levrero P; Martínez-Asuaga M; Puig S
Br J Dermatol; 2009 Sep; 161(3):536-41. PubMed ID: 19523171
[TBL] [Abstract][Full Text] [Related]
18. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.
Hearle N; Damato BE; Humphreys J; Wixey J; Green H; Stone J; Easton DF; Houlston RS
Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):458-62. PubMed ID: 12556369
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
[TBL] [Abstract][Full Text] [Related]
20. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
